Compare CSTE & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | DTIL |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 97.7M |
| IPO Year | 2012 | 2019 |
| Metric | CSTE | DTIL |
|---|---|---|
| Price | $1.47 | $4.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $60.00 |
| AVG Volume (30 Days) | 94.5K | ★ 154.1K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $34.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $3.53 |
| 52 Week High | $3.72 | $8.82 |
| Indicator | CSTE | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 59.29 |
| Support Level | $0.86 | $4.17 |
| Resistance Level | $1.90 | $4.61 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 14.37 | 94.34 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.